Top Gainers of Friday (Micron Technology, NIKE, SUPERVALU INC, Arena Pharmaceuticals)

Houston, TX -- (SBWIRE) -- 03/22/2013 -- AnotherWinningTrade.com offers its daily alerts and market content newsletter to investors looking for the best information available! AnotherWinningTrade.com provides its subscribers with useful, timely information and exclusive alerts on penny stocks, mid cap stocks and large cap stocks with the potential to deliver gains of 100%-200% or more. We have the top alerts in the industry. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.

Micron Technology, Inc.(NASDAQ:MU) jumped 11.25% and is trading at $10.09. Micron Technology, Inc., is a global manufacturer and marketer of semiconductor devices, principally NAND Flash, DRAM and NOR Flash memory, as well as other memory technologies, packaging solutions and semiconductor systems for use in computing, consumer, networking, automotive, industrial, embedded and mobile products.

How Should Investors Trade MU After The Solid Jump? Let’s Find Out Here

NIKE, Inc.(NYSE:NKE) gained 11.29% and is trading at $59.65. NIKE, Inc. (NIKE) is engaged in the design, development and worldwide marketing and selling of footwear, apparel, equipment, accessories and services. NIKE is a seller of athletic footwear and athletic apparel worldwide.

Is NKE Ready To Jump Again After The Solid Momentum? Get Free Trend Analysis Here

SUPERVALU INC.(NYSE:SVU) added 5.96% and is trading at $4.96. SUPERVALU INC. (SUPERVALU) is a United States grocery channel. It operates in two segments: Retail food and Independent business. The Company leverages its distribution operations by providing wholesale distribution and logistics and service solutions to its independent retail customers through its Independent business segment.

Is SVU Buy After The Recent Price Movement? Find Out Here

Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) is higher 5.25% and is trading at $8.31. Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

Is ARNA a Buy At The Current Market Price? Don’t Miss Out Our Special Coverage Here

Disclaimer
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information
Winning Media LLC
1-800-411-7716
ir@AnotherWinningTrade.com